Cellectis SA (CLLS) Short Interest Up 36.9% in December

Cellectis SA (NASDAQ:CLLS) was the recipient of a large growth in short interest during the month of December. As of December 29th, there was short interest totalling 906,259 shares, a growth of 36.9% from the December 15th total of 661,787 shares. Currently, 2.5% of the company’s stock are short sold. Based on an average daily trading volume, of 169,255 shares, the short-interest ratio is currently 5.4 days.

Several research analysts have issued reports on CLLS shares. Oppenheimer reissued an “outperform” rating and set a $40.00 price objective on shares of Cellectis in a research report on Thursday, December 28th. Jefferies Group reissued a “buy” rating and set a $47.00 price objective on shares of Cellectis in a research report on Tuesday, September 26th. SunTrust Banks reissued a “hold” rating and set a $20.00 price objective on shares of Cellectis in a research report on Friday, October 6th. BidaskClub raised shares of Cellectis from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 4th. Finally, Zacks Investment Research downgraded shares of Cellectis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $39.29.

Several hedge funds have recently added to or reduced their stakes in the company. ARK Investment Management LLC lifted its stake in shares of Cellectis by 79.1% in the 2nd quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,784 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Cellectis by 132.1% in the 2nd quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 5,435 shares during the period. Williams Jones & Associates LLC acquired a new stake in shares of Cellectis in the 2nd quarter worth $244,000. KBC Group NV acquired a new stake in shares of Cellectis in the 3rd quarter worth $366,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Cellectis in the 3rd quarter worth $517,000. Institutional investors own 16.35% of the company’s stock.

Shares of Cellectis (NASDAQ CLLS) opened at $29.89 on Friday. Cellectis has a 52 week low of $17.29 and a 52 week high of $35.07. The company has a market cap of $1,050.00 and a price-to-earnings ratio of -10.83.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, November 13th. The biotechnology company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.16). Cellectis had a negative return on equity of 30.66% and a negative net margin of 217.25%. research analysts forecast that Cellectis will post -2.89 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Cellectis SA (CLLS) Short Interest Up 36.9% in December” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/19/cellectis-sa-clls-short-interest-up-36-9-in-december.html.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply